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Cylindromatosis (CYLD) was originally identified as a tumor suppressor, because loss of its function causes a 
benign human tumor. In the past, multitude of  efforts have been made toward elucidating the biological 
features of CYLD, and uncovered not only its multiple functions as deubiquitinase, but also the clinical 
significance of CYLD in a wide variety of diseases. At present, dysregulation of CYLD by loss of its expression is 
believed to play key roles in a multiple of pathological processes, including tumor cell proliferation, survival, and 
inflammatory responses by regulating their specific cell signaling pathway. Recently, we discovered that loss of 
CYLD expression in hypoxic regions of human glioblastoma multiforme (GBM), the most aggressive brain 
tumor, suggesting the clinical significance of CYLD in the pathogenesis of GBM. Here, we reviewed the diverse 
biological features and clinical significance of CYLD, particularly focusing on the roles of CYLD as a critical 
regulator of hypoxia-mediated inflammation in GBM.  
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CYLD 
In 2000, Bignell and colleagues identified the familial 
cylindromatosis tumor suppressor gene (CYLD) by 
determining germline mutations in cylindromatosis families 
[1]. Tumor suppressor CYLD gene is localized on 
chromosome 16q12.1 and encodes a protein of 956 amino 
acids. CYLD was initially reported when it was identified 
that a mutation in the gene causes the formation of benign 
tumors in skin appendages [1]. Subsequent studied have 
revealed that CYLD acts as a negative regulator for nuclear 
factor-B (NF-B) signaling by deubiquitinating tumor 
necrosis factor (TNF) receptor-associated factor (TRAF) 2, 
TRAF6, and NF-B essential modulator (NEMO, also 
known as IB kinase ) [2-4]. The deubiquitinating enzyme 
CYLD contains ubiquitin carboxy-terminal hydrolases that 
bind to ubiquitin chain and detach it from a target protein [5]. 
In patients with familial cylindromatosis, malfunction of 
deubiquitinating enzyme CYLD increases resistance to 
apoptosis caused by NF-B overactivation, suggesting a 
mechanism through which loss of CYLD leads to 
tumorigenesis [1-4].   
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Polymerization of ubiquitin attached to a pre-existing 
protein typically arises by linking the carboxy-terminal 
glycine of ubiquitin to internal lysine of another ubiquitin, 
and regulates diverse biological processes, such as protein 
degradation, trafficking and signal transduction [6 - 8]. Among 
the various types of polyubiquitination chains, CYLD 
specifically binds ubiquitin chains linked by K63 and 
removes them from the target protein [9]. Since the 
K63-linked ubiquitin chain associates various 
non-degradative cell responses, such as cell signal 
transduction, CYLD is believed to play key roles in not only 
tumor cell-specific responses, but also in a multiple of 
biological responses including cell proliferation, survival, 
and inflammatory responses by regulating their specific cell 
signaling pathway [5].  
Roles of CYLD in inflammatory responses 
Although inflammation is primary response to hazardous 
stimuli and is a crucial part of the innate immune response 
acting to signal the host to any bodily insult, excessive 
inflammatory response is obviously harmful to the host, 
because of severe tissue damage [10-12]. To prevent 
detrimental excessive inflammatory response, the 
inflammatory signaling pathways must be tightly controlled.  
During evolution, the host has developed a variety of 
biological systems to avoid detrimental inflammatory 
response. Among such systems, negative feedback regulation 
is considered to play a crucial role in preventing overactive 
inflammation by strictly regulating the activation of the key 
receptor-dependent signaling adaptor molecules [13]. 
Among various cell signaling pathways, activation of 
NF-B, a primary mediator of inflammatory responses, plays 
key roles in regulating inflammatory and immune responses 
[14-16]. In addition to well-known roles that induction of IB 
plays in inhibiting the transient nature of NF-B activation, 
NF-B-dependent CYLD up-regulation that in turn leads to 
the inhibition of NF-B especially in more delayed or 
persistent phase in an auto-regulatory feedback manner [17]. 
In the NF-B regulatory signaling pathway, CYLD 
specifically targets and deubiquitinates the upstream kinase 
of IB, such as NEMO, TRAF2, TRAF6, TRAF7, TRIP, 
and TAK1, leading to its inactivation [2, 3, 4, 18-20]. Because the 
CYLD expression is itself under the control of NF-B 
activation, CYLD participates a negative feedback regulation 
of NF-B and is essential for ensuring the proper control of 
NF-κB activation in the transient and the delayed or 
persistent phases [17, 18]. Moreover, in review of all known 
shared signaling upstream transducers, TRAFs targeted by 
CYLD, have been shown to be critically involved in 
activation of not only NF-κB, but also various inflammatory 
signaling molecule, such as p38 mitogen-activated protein 
(MAP) kinase and c-jun N-terminal kinase (JNK) [18, 21-23]. 
Thus, controlled CYLD expression plays a critical roles in 
tight regulation of a wide variety of inflammatory response. 
Down-regulation of CYLD 
Over the past decade, based on its important roles in cell 
signaling regulation, a number of progress has been made for 
determining the biological functions of CYLD, by utilizing 
molecular biological tools to induce loss of CYLD function.  
Reiley et al. generated CYLD-deficient mice and reported 
that CYLD served as a positive regulator of proximal T cell 
receptor signaling in thymocytes by physical interaction with 
active Lck and promoted recruitment of active Lck to its 
substrate, Zap70 [24]. CYLD deficiency developed a tendency 
to chemically induced skin tumors caused by tumor 
formation and keratinocyte proliferation through 
overactivation of Bcl-3-Dependent NF-κB Signaling [25]. Lim 
et al. showed that, in CYLD-deficient mice, lung tissue 
exhibited increased leukocyte infiltration in response to 
bacterial infections compared to the wild-type (WT) mice [26, 
27]. Concurrently, CYLD-deficient mice also had 
up-regulated proinflammatory cytokines in response to 
Nontypeable Haemophilus influenzae [27]. Moreover, lack of 
CYLD caused the development of lung fibrosis in mice with 
Streptococcus pneumoniae infection [28]. CYLD suppressed 
transforming growth factor-β-signaling and prevented lung 
fibrosis by destabilizing Smad3 in an E3 ligase carboxy 
terminus of Hsc70-interacting protein-dependent manner, 
indicating a critical role for CYLD in tightly controlling the 
resolution of lung injury and preventing lung fibrosis [28]. 
These lines of evidence unveiled the precise biological roles 
of CYLD in a variety of diseases, and also implicated the 
potential possibility that malfunction of CYLD by loss of its 
expression, rather that its mutant, may trigger the various 
types of pathogenesis. 
In clinical, in addition to the multiple reports showing 
functional dysregulation of CYLD by various gene deletion 
or mutation, a growing body of evidence is accumulating to 
show that loss of CYLD expression can be observed in 
different types of human cancer. Hellerbrand et al. reported 
that functional relevant loss of CYLD expression contributed 
to tumor development and progression in human colon and 
hepatocellular carcinomas [29]. In malignant melanoma, 
down-regulation of CYLD expression by transcription factor 
Snail promotes tumor progression [30]. It should be noted that 
tumor thickness and progression-free and overall survival of 
patients with malignant melanoma inversely correlated with 
CYLD expression [30]. Moreover, increasing reports revealed 
that loss of CYLD expression presumably triggered the 
pathogenesis of various tumors by dysregulation of 
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biological responses, including cell proliferation, survival, 
and inflammatory responses [29 - 35]. 
Clinical significance of CYLD in glioblastoma 
Glioblastoma 
Glioblastoma multiforme (GBM), the most common 
primary tumor of the central nervous system in humans, has 
features of rapid and invasive growth in the brain [36]. Of the 
various types of glioma, GBM is the most frequent and 
aggressive, and characterized by highly malignant features. 
The median overall survival of patients with GBM who have 
standard and targeted therapies is still just more than 1 year, 
mostly because of resistance to therapy [37]. Due to their 
diffuse infiltrative features, most GBMs are not curable by 
resection, and they are extremely resistant to radiotherapy 
and/or chemotherapy. Those characteristics make GBMs 
extraordinarily lethal [38, 39]. Because few therapeutic targets 
are available for GBM, better understanding of the molecular 
mechanisms of GBM progression and therapy resistance is 
important. Recently, Song et al. have shown that, in 
malignant gliomas, CYLD reduction was found to be 
associated with glioma aggressiveness and the survival of 
patients with gliomas [40]. Moreover, Guo et al. reported the 
loss of CYLD expression in hypoxic regions of tissue 
specimens from GBMs [41]. 
Hypoxia-induced CYLD down-regulation is associated with 
the inflammatory microenvironment in GBM 
Hypoxic regions often occur in GBM, and increased tumor 
hypoxia is associated with the resistance to chemotherapy 
and radiation, and the poor prognosis of GBM patients [42]. 
Hypoxia, a characteristic and significant biological 
phenomenon of malignant tumors, frequently outpaces their 
blood supply [43]. The hypoxic microenvironment promotes 
invasion and treatment resistance of GBM cells, and 
glioma-initiating cells possess strong drug resistance and 
tumorigenicity [42, 44]. Given the well-established clinical 
relationship between increased hypoxia and GBM 
progression, targeting hypoxia-induced processes may be 
essential for developing successful treatment of GBM [42, 44, 
45]. Assessment of clinical GBM tissues and in vitro analysis 
revealed that CYLD expression was reduced under hypoxic 
conditions via transcriptional regulation in human GBM 
tissues [41]. As of this moment, transcriptional regulation of 
CYLD in tumors has yet to be determined.  Previous reports 
have shown that transcription of CYLD is directly 
suppressed by transcription factor Snail and Notch target 
Hes1, both of which are up-regulated and activated under 
hypoxic conditions [30, 46-48]. Hypoxia stimulates human 
papilloma virus-encoded E6 protein to promote 
ubiquitination and proteasomal degradation of CYLD in 
human papilloma virus-positive squamous cell carcinoma 
cell lines [49]. In addition, a number of studies showed that 
several microRNAs (miRNAs), endogenous small 
non-coding RNAs 19-24  nucleotide in length known to 
regulate gene expression, suppressed CYLD expression in 
multiple tumors [40, 50, 51]. Additional studies are needed to 
clarify the gene regulatory mechanism underlying the 
relationship between CYLD down-regulation and hypoxia. 
Inflammatory microenvironment, the seventh hallmark of 
cancer, generally promotes malignant progression [52]. 
Increasing evidence suggests the clinical significance of 
hypoxia-elicited inflammation in tumors [53]. As evidenced 
by the fact that various inflammatory cytokines promote the 
growth, survival, and invasion of GBM cells [54-56]. Increased 
Figure 1. Hypoxia suppresses CYLD expression to promote 
inflammation in glioblastoma. 
 
Inflammation & Cell Signaling 2015; 2: e479. doi: 10.14800/ics.479; ©  2015 by Hirofumi Jono, et al. 
http://www.smartscitech.com/index.php/ics 
 
Page 4 of 7 
 
expression of inflammatory cytokines including angiogenic 
mediators such as vascular endothelial growth factor (VEGF) 
has been associated with the poor prognosis of GBM [57, 58]. It 
is particularly worth noting that hypoxia promoted the 
activation of NF-B and involved in regulating the 
inflammatory microenvironment [59-62]. In fact, 
hypoxia-induced CYLD reduction was critical for 
inflammatory responses triggered by hypoxia in GBM, and 
strongly associated with GBM tumor progression including 
malignant transformation and drug resistance [41]. As stated, 
it is well-documented that CYLD acts as a negative regulator 
for NF-B signaling, a primary mediator of inflammatory 
responses [2-4]. Because TNF-α rapidly activates the NF-κB 
pathway [52], an excessive inflammatory response to the 
cytokine under hypoxic conditions may be due largely to 
CYLD down-regulation. Inhibition of several cytokine 
expression by CYLD in a hypoxia-specific manner, which 
indicated the presence of hypoxia-specific molecular 
mechanisms regulated by CYLD [41]. Taken together, 
hypoxia-induced CYLD reduction may promote 
inflammation in an autocrine and paracrine fashion in GBM 
tissues, which in turn leads to poor prognosis of GBM 
patients (Figure 1). 
Roles of CYLD in adaptive changes in GBM during 
anti-angiogenic therapy 
GBM is one of the most highly vascularized tumors and 
expresses high levels of VEGF, which is therefore an 
attractive target for anti-angiogenic therapies [63]. 
Bevacizumab, a humanized monoclonal antibody against 
VEGF, is approved for recurrent and newly diagnosed GBM 
[64]. Although clinical trials with bevacizumab produced 
impressive radiographic responses and prolongation of 
progression-free survival, GBM inevitably progresses within 
months [65], and the impact of this therapy on overall survival 
is still not clear [66, 67]. In view of basal tumor-promoting 
roles of hypoxia in GBM, recent studies suggest that 
prolonged anti-angiogenic treatment leads to tumors 
developing progressive hypoxia, which is thought to be 
critical for resistance to therapy [68, 69]. Guo et al. reported 
that chronic administration of bevacizumab, a monoclonal 
anti-VEGF antibody, induced expression of proinflammatory 
cytokines with massive infiltration of immune cells in GBM 
xenografts. Moreover, CYLD overexpression in GBM cells 
not only prevented those proinflammatory responses but also 
significantly improved the prosurvival effect of bevacizumab, 
which by itself had no impact on survival [41]. Since there 
was no apparent difference in basal vascularity, tumor 
growth, and anti-angiogenic efficacy itself by bevacizumab 
treatment, the prosurvival effect by CYLD overexpression 
may depend on modulation of phenotypic alterations 
occurring during bevacizumab treatment.   
Growing evidence implicate that anti-VEGF treatment has 
antitumor effects but simultaneously induces tumor 
adaptation and progression to greater malignancy, with 
increased invasiveness [65, 70]. Among high-grade gliomas, the 
mesenchymal type of GBM, characterized as having gene 
expression associated with tumor invasiveness, shows the 
worst prognosis with treatment resistance [71, 72]. Indeed, 
previous studies have shown that mesenchymal transition of 
GBM cells during chronic anti-VEGF treatment underlies a 
diffuse relapse, and the predominant biological process 
occurring during the transition was an inflammatory response 
[73-76]. Increased infiltration of myeloid cells reflected 
recurrence after anti-angiogenic therapy, and such an 
increased myeloid cell influx correlated strongly with the 
degree of tumor hypoxia [75, 77, 78]. In bevacizumab-treated 
xenograft GBM model, CYLD clearly prevented massive 
immune cell infiltration surrounding necrotic regions, and 
pseudopalisades, a characteristic feature of GBM that is 
currently thought to indicate tumor cells’ actively migrating 
away from central hypoxic areas [41].  Since the increased 
invasiveness of GBM cells during anti-VEGF therapy is 
likely due to an enhanced inflammatory milieu associated 
with hypoxia induction, inhibition of the GBM cell-derived 
inflammatory response by CYLD overexpression led to less 
aggressiveness, including invasion, and ultimately better 
survival (Figure 2). 
Figure 2. Roles of CYLD in adaptive changes in GBM during 
anti-angiogenic therapy. 
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Conclusions 
In addition to its critical clinical significance during tumor 
progression, dysregulation of CYLD by loss of its expression, 
rather that its mutant, may be involved in the various types of 
pathogenesis. A series of evidence suggests that loss of 
CYLD expression is deeply associated with a wide variety of 
diseases, including malignant tumors, inflammatory diseases, 
infectious diseases, lung fibrosis, neural development, and 
cardiovascular dysfunction [79-85]. In this review, we 
described the clinical significance of CYLD, particularly 
focusing on the roles of CYLD as a critical regulator of 
hypoxia-mediated inflammation in GBM, which may affect 
the long-term efficacy of anti-VEGF therapy. Elucidating the 
mechanisms linking hypoxia-induced CYLD 
down-regulation and inflammation, and adaptive changes in 
GBM tissues during anti-VEGF therapy, may provide 
insights into GBM pathobiology and development of more 
effective therapeutic approaches to GBM. Recently, Komatsu 
et al. reported that Rolipram, a selective inhibitor for 
phosphodiesterase 4B (PDE4B), enhanced up-regulation of 
CYLD expression [86]. This finding suggests that 
up-regulating the CYLD expression may also have the 
potential to be promising therapeutic strategies for tumors as 
the low CYLD expression level has been reported to have an 
crucial role in the development of tumors in patients [86].  
Thus, deeper understanding of more biological features and 
clinical significance of CYLD may not only bring new 
insights into the pathogenesis of tumors, but may also open 
up novel therapeutic strategies for a wide variety of diseases. 
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